| Title |
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
|
|---|---|
| Published in |
OncoTargets and therapy, June 2016
|
| DOI | 10.2147/ott.s101319 |
| Pubmed ID | |
| Authors |
Wenhui Song, Hongshun Ma |
| Abstract |
To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated. ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044). The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 22% |
| Other | 1 | 11% |
| Professor | 1 | 11% |
| Student > Bachelor | 1 | 11% |
| Researcher | 1 | 11% |
| Other | 1 | 11% |
| Unknown | 2 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Environmental Science | 1 | 11% |
| Psychology | 1 | 11% |
| Chemistry | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 2 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2018.
All research outputs
#8,534,528
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#547
of 3,016 outputs
Outputs of similar age
#128,823
of 353,651 outputs
Outputs of similar age from OncoTargets and therapy
#27
of 124 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,651 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.